These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38180132)

  • 1. Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukaemia.
    Liang P; Xie Y; Liu Z; Wang D; Li Q; Lu Y; Xue S; Wang Y; Chen S; Wu D; Fu J
    Br J Haematol; 2024 Apr; 204(4):1219-1226. PubMed ID: 38180132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study.
    Xin F; Yu YH; Shen XL; Zhang GX
    Hematology; 2024 Dec; 29(1):2350319. PubMed ID: 38748459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypomethylating agents plus modified priming regimens compared with venetoclax-based regimens based on molecular characteristics for newly diagnosed patients with acute myeloid leukemia: a multi-center cohort study.
    Weng G; Huang J; He X; Xue T; Yang L; Zhang Y; Yu G; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; Jin H; Liu Q; Du X
    Ann Hematol; 2023 Dec; 102(12):3369-3381. PubMed ID: 37723307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
    Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
    Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis.
    Daver NG; Iqbal S; Renard C; Chan RJ; Hasegawa K; Hu H; Tse P; Yan J; Zoratti MJ; Xie F; Ramsingh G
    J Hematol Oncol; 2023 Mar; 16(1):19. PubMed ID: 36879351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia.
    Graveno ME; Carulli A; Freyer CW; Mangan BL; Nietupski R; Loren AW; Frey NV; Porter DL; Gill SI; Hexner EO; Luger SM; Martin ME; McCurdy SR; Perl AE; Babushok DV; Pratz KW
    Leuk Lymphoma; 2022 Jul; 63(7):1645-1650. PubMed ID: 35259056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy.
    Venugopal S; Shoukier M; Konopleva M; Dinardo CD; Ravandi F; Short NJ; Andreeff M; Borthakur G; Daver N; Pemmaraju N; Sasaki K; Montalban-Bravo G; Marx KR; Pierce S; Popat UR; Shpall EJ; Kanagal-Shamanna R; Garcia-Manero G; Kantarjian HM; Kadia TM
    Cancer; 2021 Oct; 127(19):3541-3551. PubMed ID: 34182597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.
    Maiti A; Qiao W; Sasaki K; Ravandi F; Kadia TM; Jabbour EJ; Daver NG; Borthakur G; Garcia-Manero G; Pierce SA; Montalbano KS; Pemmaraju N; Naqvi K; Ohanian M; Short NJ; Alvarado Y; Takahashi K; Yilmaz M; Jain N; Kornblau SM; Andreeff M; Bose P; Ferrajoli A; Issa GC; Masarova L; Thompson PA; Rausch CR; Ning J; Kantarjian HM; DiNardo CD; Konopleva MY
    Am J Hematol; 2021 Mar; 96(3):282-291. PubMed ID: 33264443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and granulocyte colony-stimulating factor chemotherapy as a first-line therapy for newly diagnosed acute myeloid leukemia: A propensity score-matched analysis.
    Huang R; He H; Xu X; Lin X; Dong Y; Wang X; Jiang F; Huang P; Mo S; Huang Z; Wang Y; Tao H; Zheng Y; Wu M; Yang C; Zheng Z; Zhao Y; Zhang Y; Li Y
    Cancer; 2024 Jul; 130(14):2472-2481. PubMed ID: 38470375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia.
    Weng G; Zhang Y; Yu G; Luo T; Yu S; Xu N; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; Shao R; Du X; Jin H; Liu Q
    J Intern Med; 2023 Mar; 293(3):329-339. PubMed ID: 36284445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers.
    Abaza Y; Winer ES; Murthy GSG; Shallis RM; Matthews AH; Badar T; Geramita EM; Kota VK; Swaroop A; Doukas P; Bradshaw D; Helenowski IB; Liu Y; Zhang H; Im A; Litzow MR; Perl AE; Atallah E; Altman JK
    Am J Hematol; 2024 Apr; 99(4):606-614. PubMed ID: 38342997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML.
    Bewersdorf JP; Shimony S; Shallis RM; Liu Y; Berton G; Schaefer EJ; Zeidan AM; Goldberg AD; Stein EM; Marcucci G; Bystrom RP; Lindsley RC; Chen EC; Ramos Perez J; Stein A; Pullarkat V; Aldoss I; DeAngelo DJ; Neuberg DS; Stone RM; Garciaz S; Ball B; Stahl M
    Blood Adv; 2024 Sep; 8(18):4845-4855. PubMed ID: 38941537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and Survival of Venetoclax Based Regimen in the Treatment of Acute Myeloid Leukemia].
    Kong FC; Qi L; Huang WF; Yu M; Zhou YL; Ji DX; Li F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1676-1683. PubMed ID: 38071045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.
    Gangat N; Karrar O; Iftikhar M; McCullough K; Johnson IM; Abdelmagid M; Abdallah M; Al-Kali A; Alkhateeb HB; Begna KH; Mangaonkar A; Saliba AN; Hefazi Torghabeh M; Litzow MR; Hogan W; Shah M; Patnaik MM; Pardanani A; Badar T; Murthy H; Foran J; Palmer J; Sproat L; Khera N; Arana Yi C; Tefferi A
    Am J Hematol; 2024 Feb; 99(2):193-202. PubMed ID: 38071734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens.
    Lachowiez CA; Loghavi S; Kadia TM; Daver N; Borthakur G; Pemmaraju N; Naqvi K; Alvarado Y; Yilmaz M; Short N; Ohanian M; Pierce SR; Patel KP; Qiao W; Ning J; Sasaki K; Takahashi K; Jabbour E; Andreeff M; Ravandi F; Kantarjian HM; Konopleva M; DiNardo CD
    Blood Adv; 2020 Apr; 4(7):1311-1320. PubMed ID: 32251497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment regimens in patients over 64 years with acute myeloid leukaemia: a retrospective single-institution, multi-site analysis.
    Sutter T; Schittenhelm M; Volken T; Lehmann T
    Hematology; 2023 Dec; 28(1):2206694. PubMed ID: 38078486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of AML1/ETO Fusion on the Efficacy of Venetoclax Plus Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia.
    Jin D; Chen H; He J; Li Y; Zheng G; Yang Y; Zhao Y; Le J; Shu W; He D; Cai Z
    Target Oncol; 2024 Mar; 19(2):237-249. PubMed ID: 38466536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
    DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
    Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia.
    Fleischmann M; Scholl S; Frietsch JJ; Hilgendorf I; Schrenk K; Hammersen J; Prims F; Thiede C; Hochhaus A; Schnetzke U
    J Cancer Res Clin Oncol; 2022 Nov; 148(11):3191-3202. PubMed ID: 35099591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Venetoclax and Azacitidine in Acute Myeloid Leukemia Compared to Azacitidine Monotherapy: Real-World Experience.
    Baba Y; Hida N; Sambe T; Abe M; Kabasawa N; Sakai H; Yoshimura K; Fukuda T
    Anticancer Res; 2024 May; 44(5):2003-2007. PubMed ID: 38677735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.